Loading...

Starpharma Holdings

ASX:SPL
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SPL
ASX
A$478M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The last earnings update was 84 days ago. More info.


Add to Portfolio Compare Print
  • Starpharma Holdings has significant price volatility in the past 3 months.
SPL Share Price and Events
7 Day Returns
0%
ASX:SPL
-2.1%
AU Pharmaceuticals
2.9%
AU Market
1 Year Returns
2%
ASX:SPL
-28.9%
AU Pharmaceuticals
4.3%
AU Market
SPL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Starpharma Holdings (SPL) 0% -4.5% 18.5% 2% 82.9% 85.5%
AU Pharmaceuticals -2.1% -5.8% -3.5% -28.9% -38.3% -26.6%
AU Market 2.9% 3.2% 5.5% 4.3% 21% 9.7%
1 Year Return vs Industry and Market
  • SPL outperformed the Pharmaceuticals industry which returned -28.9% over the past year.
  • SPL underperformed the Market in Australia which returned 4.3% over the past year.
Price Volatility
SPL
Industry
5yr Volatility vs Market

SPL Value

 Is Starpharma Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Starpharma Holdings. This is due to cash flow or dividend data being unavailable. The share price is A$1.28.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Starpharma Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Starpharma Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:SPL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.03
ASX:SPL Share Price ** ASX (2019-05-21) in AUD A$1.28
Australia Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 20.33x
Australia Market PE Ratio Median Figure of 542 Publicly-Listed Companies 16.09x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Starpharma Holdings.

ASX:SPL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:SPL Share Price ÷ EPS (both in AUD)

= 1.28 ÷ -0.03

-41.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Starpharma Holdings is loss making, we can't compare its value to the AU Pharmaceuticals industry average.
  • Starpharma Holdings is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Starpharma Holdings's expected growth come at a high price?
Raw Data
ASX:SPL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -41.92x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
64.5%per year
Global Pharmaceuticals Industry PEG Ratio Median Figure of 118 Publicly-Listed Pharmaceuticals Companies 1.52x
Australia Market PEG Ratio Median Figure of 359 Publicly-Listed Companies 1.45x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Starpharma Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Starpharma Holdings's assets?
Raw Data
ASX:SPL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.13
ASX:SPL Share Price * ASX (2019-05-21) in AUD A$1.28
Australia Pharmaceuticals Industry PB Ratio Median Figure of 26 Publicly-Listed Pharmaceuticals Companies 3.32x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.65x
ASX:SPL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:SPL Share Price ÷ Book Value per Share (both in AUD)

= 1.28 ÷ 0.13

9.93x

* Primary Listing of Starpharma Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Starpharma Holdings is overvalued based on assets compared to the AU Pharmaceuticals industry average.
X
Value checks
We assess Starpharma Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Starpharma Holdings has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SPL Future Performance

 How is Starpharma Holdings expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
64.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Starpharma Holdings expected to grow at an attractive rate?
  • Unable to compare Starpharma Holdings's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Starpharma Holdings's earnings growth to the Australia market average as it is expected to be loss making during the next 1-3 years.
  • Starpharma Holdings's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:SPL Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:SPL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 64.5%
ASX:SPL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 70.8%
Australia Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 51.4%
Australia Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 32.2%
Australia Market Earnings Growth Rate Market Cap Weighted Average 7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:SPL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:SPL Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-06-30 27 1 0 2
2020-06-30 20 4 -8 2
2019-06-30 6 -10 -13 2
ASX:SPL Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 4 -6 -11
2018-09-30 5 -8 -11
2018-06-30 5 -10 -10
2018-03-31 5 -12
2017-12-31 4 -18 -13
2017-09-30 4 -18 -14
2017-06-30 4 -17 -15
2016-12-31 1 -20 -20
2016-09-30 3 -19 -20
2016-06-30 5 -18 -21
2016-03-31 5 -17 -22

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Starpharma Holdings is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Starpharma Holdings's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:SPL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Starpharma Holdings Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:SPL Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-06-30 -0.01 -0.01 -0.01 1.00
2020-06-30 -0.01 -0.01 -0.01 1.00
2019-06-30 -0.04 -0.04 -0.04 1.00
ASX:SPL Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.03
2018-09-30 -0.03
2018-06-30 -0.03
2018-03-31 -0.03
2017-12-31 -0.04
2017-09-30 -0.04
2017-06-30 -0.04
2016-12-31 -0.05
2016-09-30 -0.06
2016-06-30 -0.06
2016-03-31 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Starpharma Holdings will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Starpharma Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Starpharma Holdings has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SPL Past Performance

  How has Starpharma Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Starpharma Holdings's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Starpharma Holdings does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Starpharma Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Starpharma Holdings's 1-year growth to the Global Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Starpharma Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Starpharma Holdings Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:SPL Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 4.37 -11.32 5.55 10.15
2018-09-30 4.67 -10.80 5.11 10.36
2018-06-30 4.96 -10.29 4.67 10.58
2018-03-31 4.65 -11.70 4.62 11.73
2017-12-31 4.34 -13.11 4.57 12.88
2017-09-30 3.99 -14.17 4.28 13.88
2017-06-30 3.65 -15.22 3.99 14.88
2016-12-31 1.38 -19.59 3.84 17.14
2016-09-30 2.98 -20.44 4.14 19.28
2016-06-30 4.57 -21.29 4.45 21.42
2016-03-31 4.67 -21.56 4.73 21.50
2015-12-31 4.70 -20.45 4.31 20.84
2015-09-30 3.20 -19.70 4.35 18.54
2015-06-30 1.70 -18.95 4.39 16.25
2015-03-31 1.48 -18.27 4.69 15.06
2014-12-31 1.27 -17.60 4.99 13.87
2014-09-30 1.26 -16.12 4.94 12.43
2014-06-30 1.25 -14.64 4.89 10.99
2014-03-31 1.56 -11.80 4.34 9.01
2013-12-31 1.86 -8.97 3.79 7.03
2013-09-30 2.15 -7.10 3.97 5.27
2013-06-30 2.43 -5.23 4.15 3.51
2013-03-31 2.71 -8.02 4.33 6.39
2012-12-31 2.99 -10.81 4.51 9.28
2012-09-30 2.95 -12.23 4.49 10.68
2012-06-30 2.90 -13.66 4.47 12.09

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Starpharma Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Starpharma Holdings has efficiently used its assets last year compared to the AU Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Starpharma Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Starpharma Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Starpharma Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SPL Health

 How is Starpharma Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Starpharma Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Starpharma Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Starpharma Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Starpharma Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1420.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Starpharma Holdings Company Filings, last reported 4 months ago.

ASX:SPL Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 47.90 0.04 44.40
2018-09-30 47.90 0.04 44.40
2018-06-30 53.28 0.05 51.32
2018-03-31 53.28 0.05 51.32
2017-12-31 55.91 0.06 49.90
2017-09-30 55.91 0.06 49.90
2017-06-30 60.98 0.07 61.19
2016-12-31 41.61 0.00 36.28
2016-09-30 41.61 0.00 36.28
2016-06-30 49.42 0.02 45.97
2016-03-31 49.42 0.02 45.97
2015-12-31 59.42 0.03 54.69
2015-09-30 59.42 0.03 54.69
2015-06-30 37.56 0.05 30.85
2015-03-31 37.56 0.05 30.85
2014-12-31 46.63 0.06 39.32
2014-09-30 46.63 0.06 39.32
2014-06-30 32.95 0.08 24.03
2014-03-31 32.95 0.08 24.03
2013-12-31 41.33 0.09 27.83
2013-09-30 41.33 0.09 27.83
2013-06-30 45.97 0.10 33.84
2013-03-31 45.97 0.10 33.84
2012-12-31 47.89 0.11 33.18
2012-09-30 47.89 0.11 33.18
2012-06-30 48.65 0.14 42.81
  • Starpharma Holdings's level of debt (0.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (0.2% vs 0.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Starpharma Holdings has sufficient cash runway for more than 3 years based on current free cash flow.
  • Starpharma Holdings has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -21.1% each year.
X
Financial health checks
We assess Starpharma Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Starpharma Holdings has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SPL Dividends

 What is Starpharma Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Starpharma Holdings dividends. Estimated to be 0% next year.
If you bought A$2,000 of Starpharma Holdings shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Starpharma Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Starpharma Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:SPL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 143 Stocks 3%
Australia Market Average Dividend Yield Market Cap Weighted Average of 415 Stocks 4.2%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.7%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:SPL Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2021-06-30 0.00 1.00
2020-06-30 0.00 1.00
2019-06-30 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Starpharma Holdings has not reported any payouts.
  • Unable to verify if Starpharma Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Starpharma Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Starpharma Holdings has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Starpharma Holdings's dividends in 3 years as they are not expected to pay a notable one for Australia.
X
Income/ dividend checks
We assess Starpharma Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Starpharma Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Starpharma Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SPL Management

 What is the CEO of Starpharma Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jackie Fairley
COMPENSATION A$1,692,817
AGE 55
TENURE AS CEO 12.8 years
CEO Bio

Dr. Jacinth K. Fairley, also known as Jackie, B.Sc., B.V.Sc.(Hons), MBA, GAICD, FTSE has been the Chief Executive Officer of Starpharma Holdings Limited since July 1, 2006 and serves as its Managing Director. Previously, Dr. Fairley served as the Chief Operating Officer of Starpharma Holdings Limited from July 4, 2005 to June 30, 2006. She served as Chief Executive Officer and Managing Director of Cerylid Biosciences Ltd. from 2001 to 2005. She has been Independent Non-Executive Director of Mirrabooka Investments Limited since February 15, 2018. She has over 25 years of experience working in the pharmaceutical and biotechnology industries. Dr. Fairley held a variety of international business development and senior management roles with various companies, including CSL and Faulding (which is now Mayne Pharma). She served as Vice President of International Business Development of Faulding’s Hospital Business for five years and she gained extensive international experience in product and technology licensing deals and managed Faulding’s global injectable development program. She has over twelve years of experience in the pharmaceutical and animal health industries with CSL Ltd. and F. H. Faulding and Co. She was a practicing veterinary surgeon prior to joining CSL in 1989. She has been an Executive Director of Starpharma Holdings Ltd since July 1, 2006. She serves as a board member of the Melbourne Business School and is a past member of the Federal Government’s Pharmaceutical Industry Working Group and the Federal Ministerial Biotechnology Advisory Council. She was the recipient of the prestigious Clemenger Medal and a number of other academic prizes. She is also a Graduate of the Australian Institute of Company Directors. Dr. Fairley holds BSc (Hons) with Pharmacology and Pathology and Bachelor of Veterinary Science degrees from Melbourne University. Dr. Fairley also obtained an MBA from the Melbourne Business School.

CEO Compensation
  • Jackie's compensation has increased whilst company is loss making.
  • Jackie's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Starpharma Holdings management team in years:

11.6
Average Tenure
  • The average tenure for the Starpharma Holdings management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Jackie Fairley

TITLE
CEO, MD & Executive Director
COMPENSATION
A$2M
AGE
55
TENURE
12.8 yrs

Nigel Baade

TITLE
CFO & Company Secretary
COMPENSATION
A$531K
TENURE
10.3 yrs

Tony Eglezos

TITLE
Vice President of Business Development
COMPENSATION
A$540K
TENURE
5.8 yrs

Jeremy Paull

TITLE
Vice President of Development & Regulatory Affairs
COMPENSATION
A$582K

David Owen

TITLE
Vice President of Research
COMPENSATION
A$532K
TENURE
13.3 yrs
Board of Directors Tenure

Average tenure and age of the Starpharma Holdings board of directors in years:

7.6
Average Tenure
64
Average Age
  • The tenure for the Starpharma Holdings board of directors is about average.
Board of Directors

Rob Thomas

TITLE
Chairman
COMPENSATION
A$130K
AGE
73
TENURE
4.9 yrs

Jackie Fairley

TITLE
CEO, MD & Executive Director
COMPENSATION
A$2M
AGE
55
TENURE
12.8 yrs

Zita Peach

TITLE
Independent Non Executive Director
COMPENSATION
A$74K
AGE
53
TENURE
7.6 yrs

Peter Turvey

TITLE
Independent Non-Executive Director
COMPENSATION
A$74K
TENURE
7.2 yrs

Dick Hazleton

TITLE
Independent Non-Executive Director
COMPENSATION
A$73K
AGE
76
TENURE
12.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
30. Apr 19 Sell FIL Limited Company 29. Mar 19 26. Apr 19 -956,045 A$1.33 A$-1,271,540
30. Apr 19 Buy FIL Limited Company 10. Jan 19 14. Mar 19 737,642 A$1.15 A$846,458
13. Jan 19 Buy FIL Limited Company 09. Jan 19 09. Jan 19 172,604 A$1.12 A$192,626
28. Dec 18 Buy Peter Turvey Individual 28. Dec 18 28. Dec 18 30,000 A$0.96 A$28,800
28. Dec 18 Buy Jacinth Fairley Individual 28. Dec 18 28. Dec 18 30,000 A$0.93 A$28,035
28. Dec 18 Buy Robert Thomas Individual 28. Dec 18 28. Dec 18 50,000 A$0.96 A$48,000
26. Dec 18 Sell FIL Limited Company 20. Dec 18 20. Dec 18 -298,792 A$1.40 A$-418,339
10. Dec 18 Buy FIL Limited Company 10. Oct 18 06. Dec 18 778,586 A$1.56 A$1,217,397
07. Oct 18 Sell FIL Limited Company 12. Sep 18 03. Oct 18 -3,291,851 A$1.57 A$-4,936,896
13. Sep 18 Sell FIL Limited Company 29. Jun 18 11. Sep 18 -3,759,915 A$1.42 A$-5,339,079
05. Jun 18 Sell FIL Limited Company 14. Jun 16 01. Jun 18 -9,405,363 A$1.64 A$-15,424,790
X
Management checks
We assess Starpharma Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Starpharma Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SPL News

Simply Wall St News

What Kind Of Shareholders Own Starpharma Holdings Limited (ASX:SPL)?

The big shareholder groups in Starpharma Holdings Limited (ASX:SPL) have power over the company. … Insider Ownership Of Starpharma Holdings The definition of an insider can differ slightly between different countries, but members of the board of directors always count. … General Public Ownership The general public, who are mostly retail investors, collectively hold 55% of Starpharma Holdings shares.

Simply Wall St -

Starpharma Holdings (ASX:SPL) Shareholders Have Enjoyed A 41% Share Price Gain

It might be of some concern to shareholders to see the Starpharma Holdings Limited (ASX:SPL) share price down 10% in the last month. … Starpharma Holdings isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … Over the last three years Starpharma Holdings has grown its revenue at 5.6% annually.

Simply Wall St -

How Much Did Starpharma Holdings Limited's (ASX:SPL) CEO Pocket Last Year?

Jackie Fairley has been the CEO of Starpharma Holdings Limited (ASX:SPL) since 2006. … This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Jackie Fairley's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Have Insiders Been Buying Starpharma Holdings Limited (ASX:SPL) Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … So before you buy or sell Starpharma Holdings Limited (ASX:SPL), you may well want to know whether insiders have been buying or selling. … In the last twelve months there was more buying than selling by Starpharma Holdings insiders

Simply Wall St -

What Did Starpharma Holdings Limited's (ASX:SPL) CEO Take Home Last Year?

Jackie Fairley has been the CEO of Starpharma Holdings Limited (ASX:SPL) since 2006. … Our data indicates that Starpharma Holdings Limited is worth AU$613m, and total annual CEO compensation is AU$2m. … It would therefore appear that Starpharma Holdings Limited pays Jackie Fairley more than the median CEO remuneration at companies of a similar size, in the same market

Simply Wall St -

Why Starpharma Holdings Limited's (ASX:SPL) Ownership Structure Is Important

Today, I will be analyzing Starpharma Holdings Limited’s (ASX:SPL) recent ownership structure, an important but not-so-popular subject among individual investors. … Ownership structure of a company has been found to affect share performance over time. … Therefore, it is beneficial for us to examine SPL's ownership structure in more detail.

Simply Wall St -

Does Starpharma Holdings Limited's (ASX:SPL) Recent Track Record Look Strong?

Assessing Starpharma Holdings Limited's (ASX:SPL) past track record of performance is an insightful exercise for investors. … Today I will assess SPL's recent performance announced on 31 December 2017 and evaluate these figures to its long-term trend and industry movements. … SPL is loss-making, with the most recent trailing twelve-month earnings of -AU$13.11m (from 31 December 2017), which compared to last year has become.

Simply Wall St -

Did Starpharma Holdings Limited's (ASX:SPL) Earnings Growth Outperform The Industry?

See our latest analysis for Starpharma Holdings Did SPL's recent earnings growth beat the long-term trend and the industry? … ASX:SPL Income Statement May 15th 18 We can further analyze Starpharma Holdings's loss by looking at what the industry has been experiencing over the past few years. … This means that even though Starpharma Holdings is presently running a loss, whatever near-term headwind the industry is facing, Starpharma Holdings is relatively better-cushioned than its peers.What does this mean?

Simply Wall St -

Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

Many investors are wondering the rate at which SPL will turn a profit, with the big question being “when will the company breakeven?” In this article, I will touch on the expectations for SPL’s growth and when analysts expect the company to become profitable. … Check out our latest analysis for Starpharma Holdings SPL is bordering on breakeven, according to analysts. … Using a line of best fit, I calculated an average annual growth rate of 117.71%, which signals high confidence from analysts.

Simply Wall St -

What Is Starpharma Holdings Limited's (ASX:SPL) Share Price Doing?

Starpharma Holdings Limited (ASX:SPL), a pharmaceuticals company based in Australia, saw significant share price volatility over the past couple of months on the ASX, rising to the highs of A$1.64 and falling to the lows of A$1.32. … According to my valuation model, Starpharma Holdings seems to be fairly priced at around 9.20% below my intrinsic value, which means if you buy Starpharma Holdings today, you’d be paying a fair price for it. … Furthermore, Starpharma Holdings’s share price also seems relatively stable compared to the rest of the market, as indicated by its low beta.

Simply Wall St -

SPL Company Info

Description

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials for the treatment of a range of tumors, such as breast, prostate, and lung; and DEP cabazitaxel that is in Phase 1/2 clinical trial for solid tumors, as well as DEP irinotecan, an anti-cancer drug used to treat colorectal cancer. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Details
Name: Starpharma Holdings Limited
SPL
Exchange: ASX
Founded: 1996
A$477,627,235
371,694,347
Website: http://starpharma.com
Address: Starpharma Holdings Limited
4-6 Southampton Crescent,
Abbotsford,
Victoria, 3067,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX SPL Ordinary Shares Australian Securities Exchange AU AUD 28. Sep 2000
OTCPK SPHR.F Ordinary Shares Pink Sheets LLC US USD 28. Sep 2000
DB PQ6 Ordinary Shares Deutsche Boerse AG DE EUR 28. Sep 2000
CHIA SPL Ordinary Shares Chi-X Australia AU AUD 28. Sep 2000
OTCPK SPHR.Y SPONSORED ADR Pink Sheets LLC US USD 20. Jan 2005
Number of employees
Current staff
Staff numbers
0
Starpharma Holdings employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/21 10:32
End of day share price update: 2019/05/21 00:00
Last estimates confirmation: 2019/04/04
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.